A comparison of patient reported outcomes in rheumatoid arthritis treated by tofacitinib versus methotrexate

Jaspreet Singh; Ajay Sharma; Harjit Kanwal Singh Chawla; Girish Sahni

doi:10.5455/njppp.2023.13.12586202223012023

2023, Vol: 13, Issue: 11

13 / 11Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

Authorship Declaration

« Previous Article

Original Research

Natl J Physiol Pharm Pharmacol. 2023; 13(2023, Vol: 13, Issue: 8): 1792-1795

doi: 10.5455/njppp.2023.13.12586202223012023

A comparison of patient reported outcomes in rheumatoid arthritis treated by tofacitinib versus methotrexate

Jaspreet Singh, Ajay Sharma, Harjit Kanwal Singh Chawla, Girish Sahni.

Abstract
Background: Rheumatoid arthritis (RA) is a chronic and debilitating autoimmune disease characterized by systemic inflammation, persistent synovitis, and joint destruction. 1 Patients and physicians rate RA disease differently — while physicians focus on RA-specific clinical and radiographic outcomes, patients focus on how their general health is affected by RA, which may lead to discordance.

Aim and Objectives: The present study plans to compare the patient reported outcomes (PRO) in RA patients treated with Methotrexate or Tofacitinib. This study was done to compare the PRO in patients taking Tofacitinib or Methotrexate. Data from a 6-month analysis are reported here.

Material and Methods: Patients presenting to outpatient department of department of orthopedics were included in this study. Patients above 18 years of age who have been previously or newly diagnosed with RA according to American College of Rheumatology criteria were included in this study. Patients were randomized into two groups who received either Tofacitinib 5 mg twice a day or Methotrexate 10 mg/week which was increased by 2.5 mg/week every 15 days to a maximum of 20 mg/week. Patient assessment was
done by Visual Analog Scale (VAS) for pain and health assessment questionnaire-disability index (HAQ-DI). This will be done at starting of treatment and then at months 1, 2, 3, and 6.

Results: Seventy-five patients received tofacitinib and 77 patients received methotrexate. There was an improvement in the disease condition as seen by VAS scale and HAQ-DI score of patients taking tofacitinib compared to methotrexate at 2, 3, and 6 months, and this difference was statistically significant.

Conclusion: Tofacitinib has a safety and efficacy profile which is similar to or superior to methotrexate.

Key words: Rheumatoid Arthritis; Tofacitinib; Methotrexate

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Jaspreet Singh Articles by Ajay Sharma Articles by Harjit Kanwal Singh Chawla Articles by Girish Sahni
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Singh J, Sharma A, Chawla HKS, Sahni G. A comparison of patient reported outcomes in rheumatoid arthritis treated by tofacitinib versus methotrexate. Natl J Physiol Pharm Pharmacol. 2023; 13(2023, Vol: 13, Issue: 8): 1792-1795. doi:10.5455/njppp.2023.13.12586202223012023

Web Style

Singh J, Sharma A, Chawla HKS, Sahni G. A comparison of patient reported outcomes in rheumatoid arthritis treated by tofacitinib versus methotrexate. https://www.njppp.com/?mno=93261 [Access: November 02, 2023]. doi:10.5455/njppp.2023.13.12586202223012023

AMA (American Medical Association) Style

Singh J, Sharma A, Chawla HKS, Sahni G. A comparison of patient reported outcomes in rheumatoid arthritis treated by tofacitinib versus methotrexate. Natl J Physiol Pharm Pharmacol. 2023; 13(2023, Vol: 13, Issue: 8): 1792-1795. doi:10.5455/njppp.2023.13.12586202223012023

Vancouver/ICMJE Style

Singh J, Sharma A, Chawla HKS, Sahni G. A comparison of patient reported outcomes in rheumatoid arthritis treated by tofacitinib versus methotrexate. Natl J Physiol Pharm Pharmacol. (2023), [cited November 02, 2023]; 13(2023, Vol: 13, Issue: 8): 1792-1795. doi:10.5455/njppp.2023.13.12586202223012023

Harvard Style

Singh, J., Sharma, . A., Chawla, . H. K. S. & Sahni, . G. (2023) A comparison of patient reported outcomes in rheumatoid arthritis treated by tofacitinib versus methotrexate. Natl J Physiol Pharm Pharmacol, 13 (2023, Vol: 13, Issue: 8), 1792-1795. doi:10.5455/njppp.2023.13.12586202223012023

Turabian Style

Singh, Jaspreet, Ajay Sharma, Harjit Kanwal Singh Chawla, and Girish Sahni. 2023. A comparison of patient reported outcomes in rheumatoid arthritis treated by tofacitinib versus methotrexate. National Journal of Physiology, Pharmacy and Pharmacology, 13 (2023, Vol: 13, Issue: 8), 1792-1795. doi:10.5455/njppp.2023.13.12586202223012023

Chicago Style

Singh, Jaspreet, Ajay Sharma, Harjit Kanwal Singh Chawla, and Girish Sahni. "A comparison of patient reported outcomes in rheumatoid arthritis treated by tofacitinib versus methotrexate." National Journal of Physiology, Pharmacy and Pharmacology 13 (2023), 1792-1795. doi:10.5455/njppp.2023.13.12586202223012023

MLA (The Modern Language Association) Style

Singh, Jaspreet, Ajay Sharma, Harjit Kanwal Singh Chawla, and Girish Sahni. "A comparison of patient reported outcomes in rheumatoid arthritis treated by tofacitinib versus methotrexate." National Journal of Physiology, Pharmacy and Pharmacology 13.2023, Vol: 13, Issue: 8 (2023), 1792-1795. Print. doi:10.5455/njppp.2023.13.12586202223012023

APA (American Psychological Association) Style

Singh, J., Sharma, . A., Chawla, . H. K. S. & Sahni, . G. (2023) A comparison of patient reported outcomes in rheumatoid arthritis treated by tofacitinib versus methotrexate. National Journal of Physiology, Pharmacy and Pharmacology, 13 (2023, Vol: 13, Issue: 8), 1792-1795. doi:10.5455/njppp.2023.13.12586202223012023

Author Login Reviewer Login About Publisher Editorial Policies Editorial Review Policy Peer Review Policy Editorial & Peer Review Process Publication Ethics and Publication Malpractice Statement Conflict of Interest Policy Plagiarism Policy Protection of Research Participants (Statement On Human And Animal Rights)Corrections, Retractions & Expressions of Concern Self-Archiving Policies Statement of Informed Consent Advertising Policy Terms of Use License Information Copyright Information

About National Journal of Physiology, Pharmacy and Pharmacology

Contact Information

How to cite this article


About National Journal of Physiology, Pharmacy and Pharmacology National Journal of Physiology, Pharmacy and Pharmacology is a monthly peer reviewed journal. The journal is having open access polic ... Read more. For best results, please use Internet Explorer or Google Chrome.	Contact Information Publisher publishernjppp@gmail.com Editorial query editornjppp1@gmail.com MOB - 8780040272